Skip to main content

RUBY-3 Clinical Study

IgA Nephropathy

RUBY-3 is a phase 1/2 clinical study that is being conducted to determine if an investigational drug called povetacicept is safe and beneficial for people with IgAN whose disease is not currently well controlled with standard medication(s).

All participants will receive povetacicept. Povetacicept is administered by injection under the skin.

Proud supporter of the IgA Nephropathy Foundation

learn more about the IgAN Foundation

Do you have IgA nephropathy?

RUBY-3 is being conducted to determine if a new investigational drug, povetacicept, is safe and potentially beneficial for people with IgA nephropathy (IgAN).

Investigational means that povetacicept is still being evaluated and is not approved by any health authority (e.g., the United States Food and Drug Administration (FDA)) for IgAN or another condition.

Additional information is available at RUBY-3 ClinicalTrials.gov.

Who can join RUBY-3?

  • 18 years of age or older
  • have IgAN that is confirmed by a biopsy
  • currently have active IgAN despite receiving standard study treatment(s)

Additional requirements apply. Our study doctors can help determine if you qualify.

learn more about clinical studies and povetacicept

What happens if I join the study?

Participating in the study is optional. Before joining RUBY-3, you will be told what to expect, including the study visit schedule and what might happen at each visit. You will have a chance to ask questions and time to decide if you want to take part.

If your study physician determines you are a candidate you will be given the option to join the study. The periods of the study are:

1

Screening (up to 28 days)

Undergo tests to confirm you qualify
2

Initial Treatment Period (approximately 6 months)

Attend visits approximately every 2 weeks to undergo study tests and receive a subcutaneous (under the skin) injection of povetacicept approximately every 4 weeks
3

Extension Period (approximately 6 months)

If your study doctor thinks povetacicept is helping your IgAN, you may continue to receive the study drug approximately every 4 weeks for an additional 6 months
4

Optional Study Treatment Extension Period (approximately 12 months)

If your study doctor thinks povetacicept is helping your IgAN, you may choose to continue to receive the study drug approximately every 4 weeks for an additional 12 months
5

Follow-up (8 weeks)

Attend 2 final visits for safety checks

You may stop taking the study drug or leave the study at any time, and this will not affect your regular medical care.

All participants receive povetacicept provided at no cost, and reimbursement may be available for study-related expenses such as travel.